Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-064525
Filing Date
2025-05-06
Accepted
2025-05-06 16:30:27
Documents
75
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q snse-20250331.htm   iXBRL 10-Q 2057888
2 EX-31.1 snse-ex31_1.htm EX-31.1 16822
3 EX-31.2 snse-ex31_2.htm EX-31.2 18224
4 EX-32.1 snse-ex32_1.htm EX-32.1 10896
  Complete submission text file 0000950170-25-064525.txt   8443376

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT snse-20250331.xsd EX-101.SCH 1239017
78 EXTRACTED XBRL INSTANCE DOCUMENT snse-20250331_htm.xml XML 1401773
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39980 | Film No.: 25917738
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)